



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 25 February 2021

Re: Freedom of Information Request
Ref: 46-2021

Thank you for your email dated the 10th February 2021, requesting information in relation to treatment of lung cancer.

The information that you require is as follows:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Q1. In the past 3 months how many Urothelial cancer patients were treated with the following:

Between 1st November 2020 and 31st January 2021:

- **Atezolizumab = 23 patients**
- **Carboplatin with Gemcitabine = 15 patients**
- **Carboplatin with Paclitaxel = 0 patients**
- **Carboplatin single or in any other combination = Exempt under S.40**
- **Cisplatin with Gemcitabine = 31 patients**
- **Cisplatin single or in any other combination = 0 patients**
- **Nivolumab = 32 patients**
- **MVAC with G-CSF = 0 patients**
- **Pembrolizumab = Exempt under S.40**
- **Any other regimen including Paclitaxel = Exempt under S.40**
- **Any other chemo regimen**

Fluorouracil+Mitomycin+RT = 8 patients

Gemcitabine = Exempt under S.40

- **Other active systemic anti-cancer therapy [please state]**

Avelumab	Exempt under S.40
Avelumab + axitinib	22 patients
Axitinib	6 patients
Cabozantinib	38 patients
Durvalumab (Rampart Trial)	Exempt under S.40
Enfortumab Vedotin (EV 301 Trial)	Exempt under S.40
Ipilimumab + Nivolumab	11 patients
Lenvatinib + Everolimus	Exempt under S.40
Pazopanib	6 patients
Pembrolizumab + Axitinib	Exempt under S.40
Ramucirumab/Placebo	Exempt under S.40
Rogaratinib	Exempt under S.40
Sunitinib	Exempt under S.40
Tivozanib	23 patients

- **Palliative care only i.e. 1st therapeutic intervention at CCC was Specialist Palliative Care between 1st Nov 2020-31st Jan 2021 = Exempt under S.40**

Q2. Could you please provide the total number of patients with any treatment in the last three months for:

- **Total non-small cell lung cancer (NSCLC)**
477 patients treated with SACT between 1st November 2020 and 31st January 2021
- **BRAF+ non-small cell lung cancer (NSCLC)**
Information not held - We do not record BRAF status for NSCLC patients

Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

Between 1st November 2020 and 31st January 2021:

- **Afatinib = 25 patients**
- **Alectinib = 8 patients**
- **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel = 6 patients**
- **Atezolizumab monotherapy = 31 patients**
- **Bevacizumab = Exempt under S.40**
- **Brigatinib = Exempt under S.40**
- **Ceritinib = Exempt under S.40**

- **Crizotinib = Exempt under S.40**
- **Dacomitinib = Exempt under S.40**
- **Dabrafenib with Trametinib = 0 patients**
- **Docetaxel = Exempt under S.40**
- **Durvalumab = 22 patients**
- **Erlotinib = 12 patients**
- **Gefitinib = Exempt under S.40**
- **Gemcitabine = 20 patients**
- **Nintedanib with Docetaxel = Exempt under S.40**
- **Nivolumab = Exempt under S.40**
- **Osimertinib = 42 patients**
- **Paclitaxel = 21 patients**
- **Pembrolizumab chemo in combination = 58 patients**
- **Pembrolizumab monotherapy = 144 patients**
- **Pemetrexed with Carboplatin = 28 patients**
- **Pemetrexed with Cisplatin = 0 patients**
- **Vinorelbine and cisplatin/carboplatin = 42 patients**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>